Trigger spurs development of inflammatory bowel diseases; New cognitive approach on post-chemo patients;

> Tumor necrosis factor has been a big focus of drug developers targeting a variety of inflammatory bowel diseases. Now a team at Duke says that "a gene called uhrf1 acts like a kind of molecular handbrake on TNF. In the absence of uhrf1, TNF rolls out a series of pro-inflammatory and immune signals that inflame and damage the digestive tract." Release

UC Irvine investigators say that human neural stem cell therapies could help improve cognitive function after chemo. Release

Mitofusin 2 looks valuable as a target for diseases linked to loss of mitochondrial fusion. Release

Investigators are still focused on the role that cannabis can play in the development of new meds. Release

Suggested Articles

Researchers discovered that inactivating a subtype of the protein beta-arrestin-2 in mice restored the ability of the brain to dispose of toxic tau.

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.